A combinatorial screening protocol for identifying novel and highly potent dual-target inhibitor of BRD4 and STAT3 for kidney cancer therapy.

Front Pharmacol · 2025 · PMC11897524 · PMID 40078291

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

may be significantno p-value reported

Therefore, the high efficiency and specificity of BST-4 may be significant in drug development. 3.6 Kinase selectivity profile of BST-4 To further validate the selectivity of BST-4 on both BRD4 and STAT3, we performed a panel of 76 human kinases inhibitory assay on BST-4.

also in 13,097 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.